Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) granted an aggregate of 1,533 restricted stock units (RSUs) to two newly hired employees, with a Grant Date of December 31, 2025. The awards were made under the company's 2022 Inducement Stock Incentive Plan as inducements under Nasdaq Listing Rule 5635(c)(4).

Each RSU vests over three years, with 33 1/3% of the shares vesting on each consecutive anniversary of the Grant Date, subject to the recipient's continued service through each vesting date.

Key Figures

RSU awards 1,533 RSUs Aggregate inducement grants to newly hired employees as of December 31, 2025

New hires 2 employees Recipients of inducement RSU grants under 2022 Inducement Plan

Vesting period 3 years RSUs vest in three annual installments from the Grant Date

Annual vesting rate 33 1/3% per year Portion of RSUs vesting on each of three anniversaries

Grant Date December 31, 2025 Effective date of inducement RSU awards

Market Reality Check

$8.68 Last Close

Volume Volume 141,555 is 0.54x the 20-day average of 260,305, indicating lighter trading. low

Technical Shares at $7.36 are trading above the 200-day MA of $5.47 and 40.88% below the 52-week high of $12.45.

Peers on Argus 2 Up

Momentum scanner flagged peers CUE (up 15.000000596046448%) and CAMP (up 4.830000177025795%) without same-day news. With no clear move or direction provided for KPTI and mixed moves across other peers, trading appeared more stock-specific than broad sector-driven.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 08	Conference participation	Neutral	+2.4%	Announcement of participation in Baird’s Biotech Discovery Series virtual fireside chat.
Dec 01	Inducement grants	Neutral	-6.8%	Inducement stock options and RSUs granted to seven newly hired employees.
Dec 01	Conference participation	Neutral	+2.3%	Planned fireside chat at Piper Sandler 37th Annual Healthcare Conference in New York.
Nov 03	Inducement grants	Neutral	+4.7%	Grant of 800 RSUs to a new hire under the 2022 Inducement Plan.
Nov 03	Earnings results	Neutral	+4.7%	Q3 2025 results, revenue details, guidance reaffirmation, and trial/expense updates.

Pattern Detected

Recent KPTI news, including conferences, earnings, and inducement grants, has more often seen modest positive price reactions, with one negative reaction following a prior inducement grant announcement.

Recent Company History

This announcement fits a pattern of routine corporate updates for Karyopharm. Recent news included participation in investor and healthcare conferences in December 2025, with modest positive price reactions around 2–5%. Inducement grant press releases on November 3 and December 1, 2025 described similar equity awards under the 2022 Inducement Plan, with mixed reactions (one gain, one decline). The Q3 2025 earnings release highlighted revenue growth and guidance, which preceded a positive move, framing today’s RSU grants as another incremental HR-related update.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-11-03

An effective S-3 resale registration filed on Nov 3, 2025 covers up to 2,805,688 shares of common stock held or issuable to selling stockholders. Karyopharm is not selling securities in this registration and will not receive proceeds from stockholder resales, but could receive cash if outstanding warrants covered by the filing are exercised.

Market Pulse Summary

This announcement details a routine equity compensation action: Karyopharm granted 1,533 RSUs to two new employees under its 2022 Inducement Stock Incentive Plan pursuant to Nasdaq Listing Rule 5635(c)(4). The RSUs vest over three years in equal annual installments, contingent on continued service. Investors may contextualize this alongside the company’s existing resale registrations and prior inducement grants, monitoring future filings and operational updates for more material catalysts.

Key Terms

restricted stock units financial

"the Company granted an aggregate of 1,533 restricted stock units (RSUs)"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"1,533 restricted stock units (RSUs) to two newly-hired employees"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

nasdaq listing rule 5635(c)(4) regulatory

"as inducements material... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement stock incentive plan financial

"pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended"

An inducement stock incentive plan is a program that gives newly hired employees or executives shares or stock-based awards as a reward for joining a company and to encourage them to stay and perform. For investors, it matters because these grants can dilute existing shareholders, increase reported compensation costs, and signal how a company is investing in talent—similar to a signing bonus mixed with a stake in the business.

AI-generated analysis. Not financial advice.

NEWTON, Mass., Jan. 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,533 restricted stock units (RSUs) to two newly-hired employees. These RSU awards were granted as of December 31, 2025 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of each RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in 50 ex-U.S. territories and countries, including the European Union, the United Kingdom (as NEXPOVIO^®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302648334.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

What did Karyopharm (KPTI) announce on January 2, 2026 about inducement grants?

Karyopharm announced an aggregate grant of 1,533 RSUs to two new hires, granted effective December 31, 2025 under its 2022 Inducement Plan.

How do the RSU vesting terms for KPTI inducement grants work?

Each RSU award vests over three years, with 33 1/3% of underlying shares vesting on each anniversary of the December 31, 2025 Grant Date, contingent on continued service.

Why did Karyopharm use Nasdaq Listing Rule 5635(c)(4) for the RSU awards?

The awards were made as inducements material to new employees entering employment, which is covered by Nasdaq Listing Rule 5635(c)(4).

Will the KPTI inducement RSUs immediately dilute existing shareholders?

The announcement describes future vesting of RSUs; it does not state immediate share issuance or quantify dilution.

Where can investors find details about the Karyopharm 2022 Inducement Stock Incentive Plan?

Plan details are typically available in the company's SEC filings and investor relations disclosures, which describe award terms and conditions.